geneous patient groups, different outcome criteria, and a concentration on the use of metered Probably because of the additional factor of airway instability, 24 the bronchial hyperdose inhalers.
reactivity seen in cystic fibrosis differs from that seen in uncomplicated asthma. 2 The less responsive cystic fibrosis airway may require      optimally delivered, high dose, long term      bronchodilators to maximise the therapeutic The lungs of patients with cystic fibrosis are response. progressively compromised by airway obPatients with bronchial hyperreactivity are struction.
1-3 Viscid secretions, increased comperhaps those most likely to respond to nebupressibility of the airways in expiration, 4 and lised bronchodilator therapy, 20 and those whom fixed structural damage to the bronchial tree clinicians might wish to preselect for such treatfrom ongoing airway inflammation may all conment. They may form a special subgroup chartribute to symptoms. Lung function is comacterised by a more rapid clinical deterioration, promised by air trapping, loss of lung recoil, more severe disease, and more respiratory exand reduced expiratory flow, 5 6 with resulting acerbations, and are thus particularly in need wheeze and exercise limitation, 7-9 but airway of maximal therapy. 18 There is, however, no obstruction is not irreversible in all patients.
reliably easy way of identifying them. Bronchoconstriction responsive to bronchoBronchial provocation testing is the best dilator therapy makes a variable contribution method for detecting bronchial hyperreactivity to the overall airway obstruction. 3 in patients with cystic fibrosis but it is not Bronchodilators are beneficial during hosroutinely available, is poorly repeatable, 25 and pital admissions for intravenous antibiotic may not predict all patients who will benefit treatment of acute respiratory exacerbations 10 from bronchodilators. 20 when airway obstruction is often increased.
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Hordvik et al showed responsiveness to nebulised isoetherine increasing during hospitalisation, with the response significantly correlating with improvements in baseline      forced expiratory volume in one second (FEV 1 ),      forced vital capacity (FVC), and mid forced There is a paucity of acute response data to expiratory flow (FEF 25-75 ) measurements. 12 bronchodilators 26 and no studies of long term This probably reflects bronchodilator induced nebulised bronchodilator therapy in cystic fibmobilisation of secretions with resultant in-rosis. It is therefore necessary also to refer to creases in lung function.
data from work on delivery by metered dose The ability of bronchodilator drugs to in-inhaler. 19 Inhalation of high dose nebulised crease mucociliary clearance may be as im-bronchodilator for 10 minutes might reasonportant as their primary action and they are ably be expected to have the greater efficacy, particularly useful before chest physiotherapy given the viscid mucus barrier between drug or bronchial drainage. responses. Persistent airway inflammation, The potential for an additive bronchodilator rather than infection, produces the most sigeffect by combining ipratropium bromide and nificant lung damage in cystic fibrosis. 35 Even a agonist has not been widely addressed. patients with mild disease (mean FEV 1 >80% Weintraub et al studied the acute response to predicted value) show a marked inflammatory inhaled placebo, ipratropium bromide 40 g, response in the epithelial lining fluid. 36 A metaproterenol 1500 g, and combined double blind randomised study of alternate day bronchodilator therapy delivered by metered oral prednisone (2 mg/kg to a maximum of dose inhaler in 10 randomly selected adult 60 mg) in 45 children with cystic fibrosis impatients. 22 Eight had a clinically significant improved lung function and reduced the need for provement with at least one of the regimens, hospital admission. 37 Larger follow up studies, with a tendency for those who responded to however, showed an unacceptable incidence one regimen to respond to the others. Only of adverse side effects. 38 Inhaled corticotwo of the 10 patients showed a marked benefit steroids may confer clinical benefit without from combination therapy. Sanchez reported a producing these side effects, both during acute better response of respiratory function tests respiratory exacerbations 39 and as maintenance (FEV 1 increasing by 17%) and airway retherapy. [40] [41] [42] sistance to albuterol 5 mg and ipratropium (3) To reduce the progressive decline of FEV 1 . bromide 250 g delivered by nebuliser and face
Retrospective and prospective studies of inmask than to either drug when used alone in haled corticosteroids in patients with chronic a mixed patient group of children and adults.
obstructive pulmonary disease suggest that they Ipratropium bromide was needed to achieve a may reduce the rate of decline of respiratory fall in FRC and residual volume (RV). 30 function [43] [44] [45] [46] [47] [48] but there is no evidence in patients Ipratropium bromide appears to be more with cystic fibrosis. effective in patients with negative bronchoprovocation test results. 20 We recommend that all patients should have respiratory func- tion tests monitored before and after inhalation Inhaled corticosteroids have significant theorof both agonists and anticholinergic bronchoetical therapeutic potential in cystic fibrosis dilators, singly and in combination, to deterwhere ongoing inflammation is at the heart of mine the optimal treatment regimen. the disease process. It would be reasonable to consider treating those patients who have shown reversibility with bronchodilators, a his-    tory of asthma or allergy, or a previous response      to oral prednisolone, although there is no     reason to deny any patient a therapeutic trial. Zach 3 4 has proposed, on theoretical grounds, We do not know the optimal dose, nor if dethat bronchodilation may reduce end ex-livery by nebuliser is more effective than by piratory flow rates and thus perhaps reduce metered dose inhaler. Studies in chronic obcoughing efficiency. The relevance of this to structive pulmonary disease, however, suggest clinical practice is uncertain. 31 Deterioration that high doses are needed for maximal effect. after inhaled bronchodilator treatment is Well defined, controlled clinical trials are rare 12 15 23 26 32-34 and is not a problem in practice. urgently needed. We favour twice daily, high dose (1 mg) nebulised budesonide as additional treatment for a respiratory exacerbation and for maintenance therapy. Patients already receiving  A significant percentage of adult patients with nebulised antibiotics, bronchodilators, and/or rhDNase may not comply with this additional cystic fibrosis may benefit from bronchodilator encroachment on their time, 41 especially as they lower than during placebo treatment and the improvement in respiratory function was mainare unlikely to perceive any immediate benefit, and should be offered treatment with metered tained.
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Subgroup analysis of the phase III study dose inhalers.
showed that patients with mild lung disease (baseline FVC >85% predicted) also benefited from treatment with a decrease in the relative rhDNase (Dornase alpha, Pulmozyme) The epithelial lining fluid from the lung of risk of pulmonary exacerbations and an increase in FVC of about 4%. Chronic inpatients with cystic fibrosis shows a large predominance of polymorphonuclear leucocytes flammation is present even in the mildly affected lung. 36 By mobilising secretions and compared with normal controls. 36 The thick purulent sputum characteristic of cystic fibrosis decreasing the incidence of respiratory exacerbations, rhDNase may effect a delay in the is enriched with DNA derived from disintegration of these neutrophils 49 50 as the in-progression of lung disease in these patients. flammatory process outstrips the ability of deoxyribonuclease 1 (DNase 1), a naturally occurring human enzyme, to digest extra-  Early studies of rhDNase use in acute rescellular DNA. The latter is a viscous polyanion and a major determinant of the viscosity of the piratory exacerbations and severe disease (FVC <40%) were not sufficiently powerful to assess respiratory secretions. DNA containing fractions of the sputum may further decrease the efficacy but showed good patient tolerance of the drug. 59 60 An open label 12 week study in efficacy of treatment by binding aminoglycoside antibiotics.
51 52 the latter group has since shown a significant increase in lung function, 61 perhaps not surHuman DNase 1 has been cloned, sequenced, and expressed as recombinant prising as all severely affected patients are likely to have markedly increased levels of DNA in DNase 1, rhDNase (Pulmozyme), and shown to reduce dramatically the viscosity of the spu-their sputum. Compared with placebo, FEV 1 increased by 7% and FVC by 5% with treattum in cystic fibrosis. 50 Well defined phase I, II, and III trials of rhDNase in patients with ment. The study power was insufficient to show a significant reduction in infective exmild to moderate cystic fibrosis (FVC >40% predicted) have shown that it results in a mod-acerbations in the treatment group. est improvement in respiratory function and a modest decrease in the frequency of respiratory exacerbations.
   DN     Patients should commence treatment with rhDNase under the guidance of a cystic fibrosis    , ,    In phase I studies 53 54 rhDNase was well tol-centre to ensure that they receive the proper training for drug administration, and the mainerated to a maximum dose of 30 mg/day without development of DNase antibodies and with tenance and cleaning of the equipment. 62 63 Daily treatment is necessary to maintain the significant improvement in lung function. FEV 1 increased by 10-20% from baseline but re-therapeutic benefit. Patients must use a recommended nebuliser system only and inspire turned to pretreatment levels within one week of the study. As the total sputum volume did at a normal rate and depth through a mouthpiece while sitting upright. Currently renot increase with treatment it was hypothesised that rhDNase enhanced the removal of mucus commended delivery systems include the Hudson T Up-draft II, Marquest Acorn 11, or from areas where the normal cough and mucociliary mechanisms were ineffective.
the Respirgard II with the DeVilbiss PulmoAide compressor, the Pari LC nebuliser/Pari Phase II studies confirmed the safety profile of the drug and showed short term efficacy. 55 56 Proneb compressor, the Airlife Misty with Tee Adaptor, the Pari LL with the Inhalierboy or Almost one third of patients showed a >20% increase in FEV 1 with 2.5 mg rhDNase twice Master compressor, the Aiolos with an Aiolos compressor, or a Sidestream nebuliser with a daily. 56 Both studies reported a significant reduction in subjective perception of cystic fib-CR50 compressor. 64 The latter is used by most UK centres and can be obtained through rosis related symptoms. Adverse events were limited to mild upper airway irritation.
Genentech-Roche. The more powerful CR60 compressor coupled with the Sidestream nebu-A double blind placebo controlled phase III study 57 in 968 patients over 24 weeks showed liser may be more effective in severe lung disease 65 but should not be used until evaluated a sustained improvement in FEV 1 of approximately 6% and a reduced relative risk of a by further clinical trials. Only jet nebulisers have been shown to deliver rhDNase effectively. respiratory exacerbation requiring intravenous antibiotics of 31% in patients treated with Ultrasonic devices may cause thermal coagulation of rhDNase. Battery operated comrhDNase 2.5 mg once or twice daily. Patients experienced less dyspnoea and an increased pressors have insufficient power.
The following points need to be emphasised sense of well being. The major side effect was transient voice alteration. This trial was con-when rhDNase is prescribed:
(1) To prevent degradation of the protein, tinued as an open label study of rhDNase, 2.5 mg daily, and the treatment continued to rhDNase must be protected from excessive heat and strong light. It should be stored in its be well tolerated at two years. The risk of infection related respiratory infection remained foil pouch in a refrigerator at 2-8°C. Special group.bmj.com on November 7, 2017 -Published by http://thorax.bmj.com/ Downloaded from cool boxes can be obtained for use when trav-is almost no protocol experience of doses greater than 20 mg/day. elling. rhDNase should not be used if it has been exposed to room temperature for 24 hours (2) All patients showing rapid deterioration in FEV 1 despite maximal use of routine therapy. or longer, or if it becomes cloudy or discoloured.
(3) All patients with more than usual difficulties in expectorating tenacious secretions. (2) rhDNase must not be combined with any other medications in the nebuliser as changing (4) Patients with mild to moderate disease severity (those shown to respond in phase I-III the characteristics of the solution might alter the rhDNase protein.
trials).
(5) Patients experiencing difficulty with moving (3) We recommend that rhDNase should be inhaled after morning physiotherapy or in the secretions in an acute respiratory deterioration.
We do not yet recommend prophylactic late afternoon or early evening. This will maximise the effect of the before bed physiotherapy rhDNase in those with normal FEV 1 or FVC values and no significant sputum production. session. It is advisable to leave about two hours -and an absolute minimum of half an hourbetween rhDNase inhalation and physio- ing the patient." 62 We would endorse these 19 Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellitis D,
  

